Red Tree Venture

Co-founder and managing partner of Red Tree Venture Capital, an accomplished life science investor with 40 career investments and 26 liquidity events. Previously a partner and life sciences team leader at TPG and co-founder of Novo Ventures' San Francisco office; holds a Ph.D. in Neuroscience from Stanford.

Co-founder and Chief Scientific Advisor at Red Tree, and a Stanford Professor of Bioengineering who chaired the department from 2017-2022. A serial biotech entrepreneur who founded companies including xCella Biosciences and Combangio; holds a Ph.D. in Biological Chemistry from MIT.

Managing Director at Red Tree with deep drug development and venture experience. Previously CEO of Inception Therapeutics and venture partner at Versant Ventures, and an entrepreneur-in-residence at Third Rock Ventures; holds a Ph.D. in molecular pharmacology from Stanford.

Biologics leader at Red Tree Venture Labs with nearly two decades in biotherapeutics discovery and preclinical development. Previously worked at Takeda, Denali Therapeutics, Codexis and Spotlight Therapeutics; holds a Ph.D. in chemistry from Stanford.

Executive Assistant to the Red Tree team in San Diego, with three years of executive support experience and a prior background in biotech talent acquisition. Graduated from San Diego State University.

Scientific advisory board member focused on immunology; Stanford professor and chief of the Division of Immunology and Rheumatology who studies autoimmune disease, and co-founder of Red Tree portfolio company EBVio.

Chemistry leader at Red Tree Venture Labs with over 26 years building life science companies in San Diego. Founding member of Amira Pharmaceuticals, co-founder of Inception Sciences and Pipeline Therapeutics, and former CSO of Autobahn Therapeutics; holds a Ph.D. in Chemistry from UC Irvine.

VP of Investor Relations at Red Tree with experience across venture, private equity and hedge funds, including investor relations roles at Pantera Capital, Asia Alternatives and Pantheon Ventures. Holds a B.A. from UC Davis.

Scientific advisory board member focused on oncology; Stanford professor and founding director of the Stanford Center for Cancer Cell Therapy, a pioneer in CAR T-cell therapy who has co-founded three cell therapy companies.

Operating Partner at Red Tree Venture Labs and a drug discovery leader in pharma and biotech. Held roles at GNF/Novartis, Organovo, COI Pharmaceuticals and Takeda; holds a Ph.D. from Johns Hopkins School of Medicine.

Scientific advisory board member focused on neuroscience; former chair of Stanford's Department of Neurology whose research targets mechanisms of neurodegenerative disease, and founder of PharmatrophiX.

Scientific advisory board member focused on neuroscience; Scripps Research professor and chair whose work led to the invention of ozanimod, and a scientific founder of Receptos and Blackthorn Therapeutics.

Scientific advisory board member focused on oncology; UCSF professor and former chair of Pharmaceutical Chemistry, a pioneer of protein engineering and co-founder of multiple companies including Sunesis and EpiBiologics.

Scientific advisory board member focused on immunology; Chair of Environmental Health at Harvard T.H. Chan School of Public Health and a researcher in allergy, asthma, immunology and climate-related health.

Scientific advisory board member focused on neuroscience; D.H. Chen Professor of Bioengineering and Psychiatry at Stanford and HHMI Investigator, a pioneer of optogenetics and recipient of numerous major science prizes.

Scientific advisory board member focused on immunology; Director of the Stanford Center for Human Systems Immunology and Avery Family Professor of Immunology, known for identifying T-cell receptor genes and developing peptide-MHC tetramers.

Scientific advisory board member focused on oncology; Stanford professor and co-director of Cancer Drug Discovery whose research advances kinase inhibitor and degrader design.

Scientific advisory board member focused on neuroscience; James H. Clark Professor at Stanford, founding chairman of its Bioengineering department, and a leader in movement science who has co-founded six health technology companies.

Executive Assistant to the Red Tree team with 25 years of administrative experience. Previously an EA at Homestead Capital USA and at Takeda Ventures; holds a B.A. from Hamamatsu University in Japan.

CFO of Red Tree with expertise in investment reporting, legal, compliance and administration. Managing member of venture CFO consulting firm Lomond Hill and former CFO & partner of Delphi Ventures; a CPA with a business administration degree from Cal Poly.

Director of Finance focused on fund management, administration, investor relations, and compliance. Previously provided outsourced CFO services at IQ-EQ.

Jessica Palter is Chief Legal Officer of Purpose Unlimited, responsible for the company's legal matters, and joined Purpose in 2016. Her work covers strategic initiatives, mergers and acquisitions, corporate governance, and shareholder matters, and she oversees the legal and compliance group serving Purpose's client segments. Before Purpose, she practiced corporate law at Torys LLP, focusing on mergers and acquisitions and corporate finance, and she holds common law and civil law degrees from McGill and a Bachelor of Arts from the University of Toronto.

Lourenço Teodoro is a VC investor at 33N Ventures, focusing on cybersecurity, AI, and infrastructure. He holds a Master's degree in Information Systems from Instituto Superior Técnico and previously worked as a researcher at INESC-ID on Large Language Model applications, in addition to a role in software engineering.